Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension safety and efficacy monitoring of solanezumab in mild Alzheimer's disease
2010-021155-11Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of solanezumab in Alzheimer's disease (AD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Vital signs statistically different between treatment groups and Safety assessment. Started Sep 2010; status: terminated.
02
Drugs
solanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2010-021155-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021155-11.